tm
Seeing Is Believing
tm
Seeing Is Believing
Healthcare - Sector
VRNA is currently covered by 6 analysts with an average price target of $100.4. This is a potential upside of $16.3 (19.38%) from yesterday's end of day stock price of $84.1.
Verona Pharma PLC ADR's activity chart (see below) currently has 41 price targets and 65 ratings on display. The stock rating distribution of VRNA is 100% BUY.
Analysts average stock forecasts to be materialized ratio is 75.46% with an average time for these price targets to be met of 447 days.
Highest price target for VRNA is $107, Lowest price target is $72, average price target is $60.5.
Most recent stock forecast was given by RAGHURAM SELVARAJU from HC WAINWRIGHT on 30-Apr-2025. First documented stock forecast 22-May-2017.
Currently out of the existing stock ratings of VRNA, 35 are a BUY (100%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$85
$3.8 (4.68%)
$75
1 months 3 days ago
(30-Apr-2025)
23/24 (95.83%)
$12.93 (17.94%)
311
Buy
$107
$25.8 (31.77%)
$93
1 months 3 days ago
(30-Apr-2025)
2/4 (50%)
$34.93 (48.47%)
103
Buy
$72
$-9.2 (-11.33%)
$44
3 months 21 days ago
(12-Feb-2025)
13/13 (100%)
$9.3 (14.83%)
431
Buy
$34
$-47.2 (-58.13%)
$31
1 years 1 months 10 days ago
(23-Apr-2024)
4/4 (100%)
$18.41 (118.09%)
697
Buy
$33
$-48.2 (-59.36%)
$30
1 years 3 months 1 days ago
(01-Mar-2024)
6/6 (100%)
$14.81 (81.42%)
922
What is VRNA (Verona Pharma PLC ADR) average time for price targets to be met?
Which analyst has the current highest performing score on VRNA (Verona Pharma PLC ADR) with a proven track record?
Which analyst has the current lower performing score on VRNA (Verona Pharma PLC ADR) with a proven track record?
Which analyst has the most public recommendations on VRNA (Verona Pharma PLC ADR)?
Which analyst is the currently most bullish on VRNA (Verona Pharma PLC ADR)?
Which analyst is the currently most reserved on VRNA (Verona Pharma PLC ADR)?
